FDA Looks to Boost Industry Competition Through Deregulation

Generic Line
A A
The FDA is using President Trump’s mandate to shrink the size of the government’s regulatory footprint as an opportunity to re-examine how its rules may be misused to delay generic competition — and to clear the decks of older regulations that advances in science have made obsolete, a senior HHS official told lawmakers.

To View This Article:

Login

Subscribe To Generic Line